Search Options Stock News and Analysis from Schaeffer's

Why Acadia Pharmaceuticals Stock's Rally Could Have Legs

https://www.schaeffersresearch.com/content/analysis/2022/10/04/why-this-biotech-stocks-rally-could-have-legs

10/4/2022 2:19 PM

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is up 3.3% to trade at $17.60 at last check, as the broader market looks to extend its early October rally. The shares are eyeing their third-straight...

Biotech Stock Plummets After FDA Snub

https://www.schaeffersresearch.com/content/news/2022/06/21/biotech-stock-plummets-after-fda-snub

6/21/2022 10:30 AM

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock is one of the worst stocks on the Nasdaq today, down 35.6% to trade at $12.56 at last check. On Friday, the U.S. Food and Drug Administration (FDA) advi...

ACAD Rises on Acquisition, Initiated Coverage

https://www.schaeffersresearch.com/content/news/2020/08/25/acad-rises-on-acquisition-initiated-coverage

8/25/2020 10:38 AM

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is up 1.15% to trade at $38.40 at last check, after announcing its acquisition of CerSci Therapeutics. The deal will further Acadia's non-opioid pain therapies...

Biotech Could Burst Higher, Says Signal

https://www.schaeffersresearch.com/content/analysis/2020/06/29/biotech-could-burst-higher-says-signal

6/29/2020 3:50 PM

The shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been trading in a channel of higher highs lately, contained by the $45 and $50 levels during the past three months. The stock has made sev...

Analysts React to ACADIA Trial Update

https://www.schaeffersresearch.com/content/news/2019/11/26/analysts-react-to-acadia-trial-update

11/26/2019 9:32 AM

It's been a huge year for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), thanks to positive updates for its drugs Nuplazid and pimavanserin, the latter of which again has the pharma name in focus. The ...

PEOPLE ALSO SEARCH FOR